Literature DB >> 14622710

Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats.

Chen-Guang Yu1, Carolyn A Fairbanks, George L Wilcox, Robert P Yezierski.   

Abstract

Intraspinal injection of the AMPA/metabotropic receptor agonist quisqualic acid (QUIS) results in a pathophysiology that leads to excessive grooming behavior, which has been proposed as a model of spontaneous at-level pain after spinal cord injury (SCI). To further characterize the onset and progression of this behavior we evaluated the effects of 3 drugs, agmatine (Agm), interleukin-10 (IL-10), and cyclosporin A (CsA), on different characteristics of this behavior. In these experiments rats were given saline, Agm, CsA10, or CsA20 once daily for 14 days (or a single injection of IL-10) starting either 30 minutes post-QUIS (group 1) or 10 to 18 days post-QUIS when excessive grooming behavior had been established (group 2). In the first group of animals agmatine, IL-10, CsA10, or CsA20 reduced the longitudinal extent of neuronal loss in the spinal cord compared to QUIS-injected animals treated with saline. The behavioral consequences of this effect included the delayed onset of excessive grooming behavior, reduction in the area of skin targeted for excessive grooming, and reduced grooming severity. Animals treated at the time of excessive grooming onset showed significantly reduced grooming area, grooming severity, and neuronal loss in the spinal cord compared to QUIS animals treated with saline. In conclusion, systemic administration of Agm, IL-10, or CsA significantly delayed the onset and reduced the severity of a spontaneous pain-like behavior. These effects are believed to be due, in part, to the neuroprotective properties of these drugs against QUIS-induced excitotoxicity. The effective treatment of excessive grooming behavior suggests that Agm, IL-10, and CsA modulate ongoing cellular events responsible for the progression of this behavior.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14622710     DOI: 10.1054/jpai.2003.11

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  17 in total

1.  Evaluation of the pathologic characteristics of excitotoxic spinal cord injury with MR imaging.

Authors:  Sara A Berens; Daniel C Colvin; Chen-Guang Yu; Robert P Yezierski; Thomas H Mareci
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

Review 2.  Glia in pathological pain: a role for fractalkine.

Authors:  E D Milligan; E M Sloane; L R Watkins
Journal:  J Neuroimmunol       Date:  2008-06-10       Impact factor: 3.478

Review 3.  Locomotor dysfunction and pain: the scylla and charybdis of fiber sprouting after spinal cord injury.

Authors:  Ronald Deumens; Elbert A J Joosten; Stephen G Waxman; Bryan C Hains
Journal:  Mol Neurobiol       Date:  2008-04-15       Impact factor: 5.590

4.  Predifferentiated embryonic stem cells prevent chronic pain behaviors and restore sensory function following spinal cord injury in mice.

Authors:  Wesley A Hendricks; Elena S Pak; J Paul Owensby; Kristie J Menta; Margarita Glazova; Justin Moretto; Sarah Hollis; Kori L Brewer; Alexander K Murashov
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

5.  OCT2 and MATE1 provide bidirectional agmatine transport.

Authors:  Tate N Winter; William F Elmquist; Carolyn A Fairbanks
Journal:  Mol Pharm       Date:  2010-12-03       Impact factor: 4.939

Review 6.  Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence.

Authors:  Soundar Regunathan
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

7.  Sensory stimulation prior to spinal cord injury induces post-injury dysesthesia in mice.

Authors:  Emily L Hoschouer; Taylor Finseth; Sharon Flinn; D Michele Basso; Lyn B Jakeman
Journal:  J Neurotrauma       Date:  2010-05       Impact factor: 5.269

8.  PEGylation of interleukin-10 for the mitigation of enhanced pain states.

Authors:  Ryan G Soderquist; Erin D Milligan; Jacqueline A Harrison; Raymond A Chavez; Kirk W Johnson; Linda R Watkins; Melissa J Mahoney
Journal:  J Biomed Mater Res A       Date:  2010-06-01       Impact factor: 4.396

9.  Interleukin-10 of red nucleus plays anti-allodynia effect in neuropathic pain rats with spared nerve injury.

Authors:  Zhi-Hong Wang; Xiao-Yan Zeng; Shui-Ping Han; Gui-Xiang Fan; Jun-Yang Wang
Journal:  Neurochem Res       Date:  2012-05-15       Impact factor: 3.996

Review 10.  Spinal interleukin-10 therapy to treat peripheral neuropathic pain.

Authors:  Erin D Milligan; Kathryn R Penzkover; Ryan G Soderquist; Melissa J Mahoney
Journal:  Neuromodulation       Date:  2012-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.